- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05567770
ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer (ACTION)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a two cohort pilot study for patients with hormone-sensitive prostate cancer after primary treatment +/- salvage treatment with metastases detected on PSMA-PET scan but equivocal, indeterminate or absent on conventional imaging.
Cohort 1 will have patients with Oligometastatic (low volume, between 1 and 5 metastases) disease and Cohort 2 will have patients with polymetastatic (high volume, ≥5 metastases) disease detected via PSMA PET.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medicine - New York Presbyterian Hospital
-
Principal Investigator:
- Jones Nauseef, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma, at any time before registration.
- Age ≥ 18 years
- ECOG Performance Status 0-2.
- Prior curative-intent treatment to the prostate, by either:
- External beam and/or brachytherapy to: Prostate alone, prostate and seminal vesicles, prostate and pelvic nodes, or radiation to all three sites.
- Radical prostatectomy alone, radical prostatectomy plus postoperative radiotherapy to the prostate bed, or radical prostatectomy plus postoperative radiotherapy to the pelvic nodes.
- Must meet study entry criteria based on the following diagnostic workup within 120 days prior to enrollment: • History and physical examination
- 99mTc bone scan (Must be negative or equivocal);
- Either CT or MRI of pelvis +/- abdomen (Must be negative or equivocal);
- PSMA PET scan (Must be positive with exception of local disease); Note: All 3 scans are mandatory (bone scan; CT/MR; PET)
- Serum total testosterone >100 ng/dL within 120 days prior to enrollment.
- Be willing to use effective contraception during the entire study period.
- To have adequate organ and marrow function, as defined below:
- a. Absolute neutrophil count (ANC) of ≥2,000/mm3
- b. Hemoglobin ≥9 g/dL without need for transfusion
- c. Platelet count ≥150,000/mm3 and absent history or primary quantitative or qualitative platelet defect
- d. Serum creatinine of ≤1.5 x ULN or calculated creatinine clearance of ≥60 mL/min/1.73 m2 by Cockcroft-Gault (or determined by 24 hour urine collection)
- e. Serum total bilirubin ≤1.5 x ULN (unless due to Gilbert's syndrome, in which case direct bilirubin must be normal)
- f. Serum AST and ALT ≤1.5 x ULN.
Exclusion Criteria:
- 1. Currently on androgen deprivation or anti-androgen therapy.
- Definitive radiologic evidence of metastatic disease on conventional imaging, defined by one of the following:
- a. osseous metastasis on 99mTc radionuclide bone scan, or
- b. extra pelvic nodal/soft tissue disease (> 1.5cm in short axis) on CT or MRI pelvis +/- abdomen
- Spinal cord compression, or spinal intramedullary, brain, and/or visceral (for example liver, lung, etc.) metastasis. Note: Spinal metastases (PSMA PET- detected) with epidural extension are eligible if there is >0.3cm spatial separation between the gross tumor volume and spinal cord.
- Biopsy-proven prostatic carcinoma with signet-ring, sarcomatoid, or neuroendocrine features (for example, small cell).
- Prior metastatic or non-metastatic, invasive malignancy (except non metastatic, non-melanomatous skin cancer) unless continuously disease free for > 3 years.
- Prior chemotherapy for prostate cancer or bilateral orchiectomy. Note: Prior chemotherapy for a different cancer is allowed if continuously disease-free for > 3 years.
- Intrapelvic lymph nodes as only site of prostate cancer recurrence.
- Received a platelet transfusion within 4 weeks of treatment
- Received growth factors for white blood cells or platelets within 4 weeks of treatment
- Prior treatment with unsealed radiation sources such as 89Strontium or 153Samarium-containing compounds (e.g. Metastron, Quadramet)
- History of prior PSMA-TRT
- Known history of myelodysplastic syndrome
- Other serious illness(es) involving the cardiac, respiratory, central nervous, renal, hepatic, or hematological systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cohort 1
|
Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
Other Names:
|
Active Comparator: Cohort 2
|
Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Limiting Toxicity (DLT) Rate
Time Frame: 24 months
|
A DLT will is defined as a grade 3 or higher hematologic adverse event or a grade 2 or higher non-hematologic adverse event deemed to be at least possibly related to study treatment.
Adverse events will be assessed using CTCAE version 5. Patients will be observed for a DLT for 3 months from the second dose of actinium-J591.
|
24 months
|
Change in Maximum Tolerated Dose (MTD)
Time Frame: 3,6,12,18 and 24 months.
|
3,6,12,18 and 24 months.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival (PFS) on conventional Imaging
Time Frame: 3 months
|
3 months
|
Progression Free Survival (PFS) on conventional Imaging
Time Frame: 6 months
|
6 months
|
Progression Free Survival (PFS) on conventional Imaging
Time Frame: 12 months
|
12 months
|
Progression Free Survival (PFS) on conventional Imaging
Time Frame: 24 months
|
24 months
|
Progression Free Survival (PFS) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.
Time Frame: 3 months
|
3 months
|
Progression Free Survival (PFS) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.
Time Frame: 6 months
|
6 months
|
Progression Free Survival (PFS) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.
Time Frame: 12 months
|
12 months
|
Progression Free Survival (PFS) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.
Time Frame: 24 months
|
24 months
|
Changes in PSMA expression measured by comparison of SUV on PSMA PET scans before and after treatment
Time Frame: 3, 6, 12, and 24 months
|
3, 6, 12, and 24 months
|
Change in Percentage of PSA decline
Time Frame: 3, 6, 12, 15, 18, 21, and 24 months.
|
3, 6, 12, 15, 18, 21, and 24 months.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Himanshu Nagar, M.D., Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Androgens
Other Study ID Numbers
- 22-08025155
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer Metastatic
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.RecruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
WntResearch ABCompletedMetastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Colon CancerDenmark, United Kingdom
Clinical Trials on Actinium-J591
-
Weill Medical College of Cornell UniversityCompletedKidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | GliomasUnited States
-
Weill Medical College of Cornell UniversityCompleted
-
Weill Medical College of Cornell UniversityCompleted
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell UniversityCompleted
-
Janssen Research & Development, LLCRecruitingAdenocarcinoma | Prostatic NeoplasmsUnited States
-
Weill Medical College of Cornell UniversityUnited States Department of DefenseActive, not recruitingProstate CancerUnited States
-
Weill Medical College of Cornell UniversityCompletedProstate CancerUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Completed
-
Weill Medical College of Cornell UniversityCompletedProstate CancerUnited States
-
Weill Medical College of Cornell UniversityTerminated